|
1
|
Rastogi P, Anderson SJ, Bear HD, Geyer CE,
Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil
SR, et al: Preoperative chemotherapy: Updates of national surgical
adjuvant breast and bowel project protocols B-18 and B-27. J Clin
Oncol. 26:778–785. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schmidt-Hansen B, Klingelhöfer J,
Grum-Schwensen B, Christensen A, Andresen S, Kruse C, Hansen T,
Ambartsumian N, Lukanidin E and Grigorian M: Functional
significance of metastasis-inducing S100A4(Mts1) in tumor-stroma
interplay. J Biol Chem. 279:24498–24504. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Garrett SC, Varney KM, Weber DJ and
Bresnick AR: S100A4, a mediator of metastasis. J Biol Chem.
281:677–680. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Emberley ED, Murphy LC and Watson PH: S100
proteins and their influence on pro-survival pathways in cancer.
Biochem Cell Biol. 82:508–515. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee WY, Su WC, Lin PW, Guo HR, Chang TW
and Chen HH: Expression of S100A4 and Met: Potential predictors for
metastasis and survival in early-stage breast cancer. Oncology.
66:429–438. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rudland PS, Platt-Higgins A, Renshaw C,
West CR, Winstanley JH, Robertson L and Barraclough R: Prognostic
significance of the metastasis-inducing protein S100A4 (p9Ka) in
human breast cancer. Cancer Res. 60:1595–1603. 2000.PubMed/NCBI
|
|
7
|
Kikuchi N, Horiuchi A, Osada R, Imai T,
Wang C, Chen X and Konishi I: Nuclear expression of S100A4 is
associated with aggressive behavior of epithelial ovarian
carcinoma: An important autocrine/paracrine factor in tumor
progression. Cancer Sci. 97:1061–1069. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim JH, Kim CN, Kim SY, Lee JS, Cho D, Kim
JW and Yoon SY: Enhanced S100A4 protein expression is clinic
pathologically significant to metastatic potential and p53
dysfunction in colorectal cancer. Oncol Rep. 22:41–47. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Agerbaek M, Alsner J, Marcussen N,
Lundbeck F and Von der Maase H: Focal S100A4 protein expression is
an independent predictor of development of metastatic disease in
cystectomized bladder cancer patients. Eur Urol. 50:777–785. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Andersen K, Nesland JM, Holm R, Flørenes
VA, Fodstad Ø and Maelandsmo GM: Expression of S100A4 combined with
reduced E-cadherin expression predicts patient outcome in malignant
melanoma. Mod Pathol. 17:990–997. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taylor S, Herrington S, Prime W, Rudland
PS and Barraclough R: S100A4(p9Ka) protein in colon carcinoma and
liver metastases: Association with carcinoma cells and
T-lymphocytes. Br J Cancer. 86:409–416. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Komatsu K, Murata K, Kameyama M, Ayaki M,
Mukai M, Ishiguro S, Miyoshi J, Tatsuta M, Inoue M and Nakamura H:
Expression of S100A6 and S100A4 in matched samples of human
colorectal mucosa, primary colorectal adenocarcinomas and liver
metastases. Oncology. 63:192–200. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kriajevska M, Tarabykina S, Bronstein I,
Maitland N, Lomonosov M, Hansen K, Georgiev G and Lukanidin E:
Metastasis-associated Mts1(S100A4) protein modulates protein kinase
C phosphorylation of the heavy chain of nonmuscle myosin. J Biol
Chem. 273:9852–9856. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen ZW and Liao ML: RECIST criteria used
in evaluating the efficacy of cancer therapy. Zhong Guo Ai Zheng.
10:6–8. 2004.(In Chinese).
|
|
15
|
Corben AD, Abi-Raad R, Popa I, Teo CH,
Macklin EA, Koerner FC, Taghian AG and Brachtel EF: Pathologic
response and long-term follow-up in breast cancer patients treated
with neoadjuvant chemotherapy: A comparison between classifications
and their practical application. Arch Pathol Lab Med.
137:1074–1082. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu G and Wang YS: Progress of
breast-conserving surgery after neoadjuvant chemotherapy for breast
cancer. Zhongguo Pu Wai Ji Chu Yu Lin Chuang Za Zhi. 17:1249–1252.
2010.(In Chinese).
|
|
17
|
Ring AE, Smith IE, Ashley S, Fulford LG
and Lakhani SR: Oestrogen receptor status, pathological complete
response and prognosis in patients receiving neoadjuvant
chemotherapy for early breast cancer. Br J Cancer. 91:2012–2017.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fisher ER, Wang J, Bryant J, Fisher B,
Mamounas E and Wolmark N: Pathbiology of preoperative chemotherapy:
Findings from the national surgical adjuvant breast and bowel
(NSABP) protocol B-18. Cancer. 95:681–695. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Zhang DL, Jiao XL and Dong Q:
S100A4 regulates migration and invasion in hepatocellular carcinoma
HepG2 cells via NF-κB-dependent MMP-9 signal. Eur Rev Med Pharmacol
Sci. 17:2372–2382. 2013.PubMed/NCBI
|
|
20
|
Helfman DM, Kim EJ, Lukanidin E and
Grigorian M: The metastasis associated protein S100A4: Role in
tumor progression and metastasis. Br J Cancer. 92:1955–1958. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Albertazzi E, Cajone F, Leone BE, Naguib
RN, Lakshmi MS and Sherbet GV: Expression of metastasis-associated
genes h-mts1 (S100A4) and nm23 in carcinoma of breast is related to
disease progression. DNA Cell Biol. 17:335–342. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang XS, Lin SS, Wang GY, Zou DL, Chen HS
and You Q: Correlation between S100A4 and E-Cad protein expression
and invasion, metastasis and prognosis of colorectal cancer.
Zhongguo Zhong Liu Lin Chuang. 36:690–693. 2009.(In Chinese).
|
|
23
|
Jin L, Shen Q, Ding S, Jiang W, Jiang L
and Zhu X: Immunohistochemical expression of Annexin A2 and S100A
proteins in patients with bulky stage IB-IIA cervical cancer
treated with neoadjuvant chemotherapy. Gynecol Oncol. 126:140–146.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ambartsumian N, Klingelhöfer J, Grigorian
M, Christensen C, Kriajevska M, Tulchinsky E, Georgiev G, Berezin
V, Bock E, Rygaard J, et al: The metastasis-associated Mts1
(S100A4) protein could act as an angiogenic factor. Oncogene.
20:4685–4695. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Q, Yu MH, Wang G and Wang MH:
Expression and clinical significance of DLL4 and S100A4 in
different molecular subtypes of breast carcinoma. Zhongguo Pu Wai
Ji Chu Yu Lin Chuang Za Zhi. 19:957–961. 2012.(In Chinese).
|
|
26
|
Chang JC, Wooten EC, Tsimelzon A,
Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK,
Chamness GC, Allred DC and O'Connell P: Gene expression profiling
for the prediction of therapeutic response to docetaxel in patients
with breast cancer. Lancet. 362:362–369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hess KR, Anderson K, Symmans WF, Valero V,
Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ,
et al: Pharmacogenomic predictor of sensitivity to preoperative
chemotherapy with paclitaxel and fluorouracil, doxorubicin and
cyclpophosphamide in breast cancer. J Clin Oncol. 24:4236–4244.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li SJ, Han B, Fu T, Shi AP, Wu D, Liu GJ
and Fan ZM: The relationship between ER, PR and the expression of
HER-2 and breast cancer neoadjuvant chemotherapy reaction. Zhong
Guo Lao Nian Xue Za Zhi. 29:474–476. 2009.(In Chinese).
|
|
29
|
MacGrogan G, Mauriac L, Durand M, Bonichon
F, Trojani M, de Mascarel I and Coindre JM: Primary chemotherapy in
breast invasive carcinoma: Predictive value of the
immunohistochemical detection of hormonal receptors, p53, c-erbB-2,
MiB1, pS2 and GST pi. Br J Cancer. 74:1458–1465. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou QH, Wu Y, Cai ZR and Zhu JX:
Influence of neoadjuvant chemotherapy on ER, PR, C-erbB-2, Ki-67
expressions of breast cancer patients. Zhong Guo Ai Zheng Za Zhi.
18:139–141. 2008.(In Chinese).
|
|
31
|
Zhao YC, Li Y, Zhu YY and Luo CY:
Significance of expression changes of ER, PR, p53 and Bcl-2 induced
by neoadjuvant chemotherapy (NAC) in breast cancer. Xian Dai Zhong
Liu Yi Xue. 19:2017–2020. 2011.(In Chinese).
|
